TRIMTECH Therapeutics raises $31M to enhance its TRIMTAC platform, targeting protein aggregates in neurodegenerative diseases for improved therapeutic outcomes.
TRIMTECH Therapeutics raises $31M to enhance its TRIMTAC platform, targeting protein aggregates in neurodegenerative diseases for improved therapeutic outcomes.